drugset

drugset / Trial / NCT07713290

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

NCT07713290 ↗

Phase 1 Active not recruiting 6 enrolled Beijing Gene Key Life Technology Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.

Timeline

Start: 2025-04-03
Primary completion: 2026-11-12
Completion: 2027-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iNKT cells	Cell therapy	—	—

Indications